Z-Val-Leu-Arg-AMC
| Code | Size | Price |
|---|
| AG-CP3-0027-M005 | 5 mg | £115.00 |
Quantity:
| AG-CP3-0027-M025 | 25 mg | £400.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
Ambient
Storage:
-20°C
Documents
Further Information
Alternate Names/Synonyms:
Z-VLR-AMC . TFA
Appearance:
White to off-white solid.
EClass:
32160000
Form (Short):
liquid
Handling Advice:
Keep cool and dry.
InChi:
InChI=1S/C35H47N7O7.C2HF3O2/c1-20(2)16-27(41-33(46)30(21(3)4)42-35(47)48-19-23-10-7-6-8-11-23)32(45)40-26(12-9-15-38-34(36)37)31(44)39-24-13-14-28-25(18-24)22(5)17-29(43)49-28;3-2(4,5)1(6)7/h6-8,10-11,13-14,17-18,20-21,26-27,30H,9,12,15-16,19H2,1-5H3,(H,39,44)(H,40,45)(H,41,46)(H,42,47)(H4,36,37,38);(H,6,7)/t26-,27-,30-;/m0./s1
InChiKey:
CQGZNXISWTZIAZ-BYCMOFKSSA-N
Long Description:
Chemical. Formula: C35H47N7O7 . C2HF3O2. MW: 677.8 . 114.0. Proteasome subunit alpha type-1 (Macropain) substrate used for assaying the trypsin-like activity of the 20S proteasome. Cysteine proteinase falcipain-2 and falcipain-3 (malarial hemoglobinases) substrate. Cathepsin S substrate. Hydrolysis of this fluorogenic peptide substrate is monitored by observing fluorescence at an Excitation of 345nm and Emission at 445nm.
Molecular Formula:
C35H47N7O7 . C2HF3O2
Molecular Weight:
677.8 . 114.0
Package Type:
Plastic Vial
Product Description:
Proteasome subunit alpha type-1 (Macropain) substrate used for assaying the trypsin-like activity of the 20S proteasome. Cysteine proteinase falcipain-2 and falcipain-3 (malarial hemoglobinases) substrate. Cathepsin S substrate. Hydrolysis of this fluorogenic peptide substrate is monitored by observing fluorescence at an Excitation of 345nm and Emission at 445nm.
Purity:
>97% (HPLC)
Sequence:
Z-Val-Leu-Arg-7-amido-4-methylcoumarin
SMILES:
O=C(N[C@@H](C(C)C)C(N[C@@H](CC(C)C)C(N[C@@H](CCCNC([NH3+])=N)C(NC1=CC=C(OC(C=C2C)=O)C2=C1)=O)=O)=O)OCC3=CC=CC=C3.FC(F)(C([O-])=O)F
Solubility Chemicals:
Soluble in DMSO or DMF (both 10mg/ml).
Transportation:
Non-hazardous
UNSPSC Category:
Biochemical Reagents
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 1 year after receipt when stored at -20°C.
References
Purification and characterization of a high molecular weight proteinase (macropain) from human erythrocytes: M.J. McGuire & G.N. DeMartino; Biochim. Biophys. Acta 873, 279 (1986) | Preliminary studies on cysteine and serine proteinase activities in inflamed human gingiva using different 7-amino-4-trifluoromethyl coumarin substrates and protease inhibitors: S.W. Cox & B.M. Eley; Arch. Oral Biol. 32, 599 (1987) | Purification and characterization of a protein inhibitor of the 20S proteasome (macropain): M. Chu-Ping, et al.; Biochim. Biophys. Acta 1119, 303 (1992) | New specific assays for tonin and tissue kallikrein activities in rat submandibular glands. Assays reveal differences in the effects of sympathetic and parasympathetic stimulation on proteinases in saliva: D.K. Shori, et al.; Biochem. Pharmacol. 43, 1209 (1992) | Functional Expression of Falcipain, a Plasmodium falciparum Cysteine Proteinase, Supports Its Role as a Malarial Hemoglobinase: F. Salas, et al.; Infect. Immun. 63, 2120 (1995) | Expression and characterization of the Plasmodium falciparum haemoglobinase falcipain-3: P.S. Sijwali, et al.; Biochem. J. 360, 481 (2001) | Variably modulated gating of the 26S proteasome by ATP and polyubiquitin: X. Li & G.N. DeMartino; Biochem. J. 421, 397 (2009) | Human Cysteine Cathepsins Are Not Reliable Markers of Infection by Pseudomonas aeruginosa in Cystic Fibrosis: C. Naudin, et al.; PLoS One 6, e25577 (2011)
Related Products
| Product Name | Product Code | Supplier | Ac-Arg-Leu-Arg-AMC | AG-CP3-0013 | AdipoGen Life Sciences | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Boc-Leu-Arg-Arg-AMC | AG-CP3-0014 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Z-Leu-Leu-Nva-CHO [MG-115] | AG-CP3-0015 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Suc-Leu-Leu-Val-Tyr-AMC | AG-CP3-0016 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Z-Leu-Leu-Leu-AMC | AG-CP3-0019 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Z-Leu-Leu-Glu-AMC | AG-CP3-0022 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||